Targeting Breast Cancer with CDK Inhibitors

Current Oncology Reports

Volumn 17, Issue 5, 2015, Pages

  Mayer, Erica L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Abemaciclib; Breast cancer; CDK inhibition; Cell cycle; Hormone receptor positive; LEE011; Palbociclib

Indexed keywords

ABEMACICLIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; PALBOCICLIB; RIBOCICLIB; 5-(4-ETHYLPIPERAZIN-1-YLMETHYL)PYRIDIN-2-YL)-(5-FLUORO-4-(7-FLUORO-3-ISOPROPYL-2-METHYL-3H-BENZIMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL GROWTH; CLINICAL FEATURE; CLINICAL PATHWAY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL CYCLE; CLINICAL TRIAL (TOPIC); FEMALE;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PURINES; PYRIDINES;

EID: 84923808654     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-015-0443-3     Document Type: Review

References (32)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
2. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 2014;20:3379–83.
3. Cadoo KA, Gucalp A, Traina TA. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2014;6:123–33.
4. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103–12.
5. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8:2127–33.
6. Hui R, Macmillan RD, Kenny FS, et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res. 2000;6:2777–87.
7. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res: BCR. 2009;11:R77. Preclinical evidence supports preferential activity of palbociclib in luminal (hormone receptor positive) subtype breast cancer, as well as describes synergistic interactions when palbociclib is combined with tamoxifen and trastuzumab.
8. Watts CK, Brady A, Sarcevic B, et al. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol. 1995;9:1804–13.
9. Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer. 2011;18:333–45.
10. Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–15.
11. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10:4270s–5s.
12. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013;22:723–38.
13. Criscitiello C, Viale G, Esposito A, et al. Dinaciclib for the treatment of breast cancer. Expert Opin Investig Drugs. 2014;23:1305–12.
14. Konecny GE, Winterhoff B, Kolarova T, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17:1591–602.
15. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–38.
16. Cen L, Carlson BL, Schroeder MA, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-Oncology. 2012;14:870–81.
17. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119:4597–607.
18. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104:1862–8.
19. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res:Off J Am Assoc Cancer Res. 2012;18:568–76.
20. Slamon DJ, Hurvitz SA, Applebaum S, et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. J Clin Oncol. 2010;15s:A3060.
21. Clark AS, O'Dwyer PJ, Heitjan D, et al. A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. ASCO Meeting Abstracts. 2014;5s:A527.
22. McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012;11:2747–55.
23. DeMichele A, Clark A, Tan KS, et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb + Advanced Breast Cancer: Phase II Activity, Safety and Predictive Biomarker Assessment. Clin Cancer Res. 2014.
24. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2014. The PALOMA 1 randomized phase 2 trial established the activity of the CDK 4/6 inhibitor palbociclib, described the toxicity profile in metastatic disease, and suggested superiority over standard first-line therapy with aromatase inhibitor.
25. Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32:825–37.
26. Tate SC, Cai S, Ajamie RT, et al. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res. 2014;20:3763–74.
27. Sanchez-Martinez C, Gelbert L, Shannon H, et al. LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Mol Cancer Ther. 2011;10:B234. Abemaciclib, a CDK 4/6 inhibitor, has a differentiated activity and tolerability profile in comparison to palbociclib, and in particular, the potential ability to cross the blood brain barrier.
28. Patnaik A, Rosen L, Tolaney S, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. J Clin Oncol. 2014;325s:A534.
29. Infante JR, Shapiro G, Witteveen P, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol. 2014;5s:A2528.
30. Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26:136–49. A complex relationship exists between PI3 kinase, Rb, and CDK 4/6. This preclinical experience suggests the combination of targeted biologics: a PI3K inhibitor and a CDK 4/6 inhibitor, is active and can overcome aspects of tumor resistance to therapy.
31. O'Brien N, Di Tomaso E, Ayala R, et al. In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer Proceedings AACR:A4756 2014.
32. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19:5320–8.